Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/047885external-prioritypatent/WO2009155475A1/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of TN2010000584A1publicationCriticalpatent/TN2010000584A1/en
The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.
TNP2010000584A2009-06-192010-12-17Paediatric compositions for treating multiple scleoris
TN2010000584A1
(en)
Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis.